Small cell lung cancer can choose targeted therapy or immunotherapy, both methods can be used to inhibit cancer cells and prevent them from metastasizing and spreading to surrounding tissues and organs, so there is no question of which one of the two methods is better, and it mainly depends on the sensitivity of the patient to the drugs. When choosing targeted therapy for small cell lung cancer, it is generally recommended to use vascular-based multi-targeted tyrosine kinase inhibitors, represented by Anrotinib, Apatinib and so on. As for immunotherapy for small cell lung cancer, atilizumab, divalizumab, etc. can be used, and if the anti-cancer effect is not good, the two methods can be combined. Regarding the targeted therapy and immunotherapy for small cell lung cancer, it should also be chosen according to the individual’s condition as well as the progress of the disease, and it is recommended to synthesize the doctor’s advice before treatment.